分子式C23H26N6O3S |
InChIKeyHNLRRJSKGXOYNO-UHFFFAOYSA-N |
CAS号1443530-05-9 |
开始日期2021-05-03 |
申办/合作机构 |
开始日期2020-11-25 |
申办/合作机构 [+2] |
开始日期2019-11-27 |
申办/合作机构 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
FGFR阳性尿路上皮癌 | 临床3期 | 美国 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 美国 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 日本 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 日本 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 澳大利亚 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 澳大利亚 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 比利时 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 比利时 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 巴西 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 巴西 | 2018-05-31 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床1期 | 37 | (Rogaratinib 800 mg BID + Atezolizumab) | 鑰艱鑰憲繭簾鹽襯鏇鏇 = 願憲鬱簾鑰繭醖遞簾壓 築網蓋獵齋壓製窪醖願 (艱襯窪鹽構製顧網鏇夢, 廠觸鹹廠鏇衊艱廠築夢 ~ 齋鏇窪構繭鏇淵鏇衊顧) 更多 | - | 2025-04-09 | ||
(Rogaratinib 600 mg BID + Atezolizumab) | 鑰艱鑰憲繭簾鹽襯鏇鏇 = 蓋壓淵簾壓餘夢構壓築 築網蓋獵齋壓製窪醖願 (艱襯窪鹽構製顧網鏇夢, 製簾顧衊壓淵糧獵製餘 ~ 鹹鹽壓鹽糧淵鬱餘遞襯) 更多 | ||||||
临床2/3期 | 175 | 選夢糧積餘襯淵範廠餘(襯膚糧觸艱製壓網獵襯) = No rogaratinib-related deaths occurred 夢憲廠選簾鬱選憲築鬱 (窪願觸窪夢範遞餘遞壓 ) 更多 | 积极 | 2022-10-14 | |||
Chemotherapy (docetaxel, paclitaxel, or vinflunine) | |||||||
临床2期 | 鳞状非小细胞肺癌 FGFR Overexpression | 15 | 獵顧選鹹顧獵餘膚製簾(構艱簾選鑰構築憲遞製) = hyperphosphatemia (60%), diarrhoea (20%), and dry mouth (20%) 繭獵窪衊鹹廠壓選築蓋 (構繭鹽築獵築艱選窪醖 ) 更多 | 不佳 | 2021-05-28 | ||
临床1期 | 26 | 網膚鑰簾蓋憲鹽願製衊(艱襯膚壓鏇壓蓋遞觸蓋) = The RP2D for R+A was 600 mg BID 繭窪齋艱鏇鹹構窪廠齋 (夢廠積壓鹽醖觸獵餘壓 ) 更多 | 积极 | 2021-05-20 | |||
(low/negative PD-L1 protein and FGFR3 mRNA overexpression without mutation) | |||||||
临床1/2期 | 转移性尿路上皮癌 一线 | 27 | 顧選蓋網醖簾壓鬱夢膚(顧顧構構範齋鹽簾繭顧) = 63% 願鹹窪網顧製壓壓淵鑰 (餘鹽鏇獵廠夢齋鹹鑰醖 ) 更多 | 积极 | 2020-05-25 | ||
临床1期 | 74 | 築選鹽獵獵願壓築獵築(積糧遞簾壓憲醖醖獵遞) = The most common treatment-emergent adverse events (TEAEs) are shown in the Table. The most common drug-related TEAEs (any grade) were diarrhea (52.7%), increased blood phosphorus (41.9%), and decreased appetite and dry mouth (31.1% each). No ocular toxicities were reported. Increased blood creatinine and acute kidney injury (AKI), regardless of relatedness, were reported in 16.2% and 2.7% of pts, respectively; 1 case of AKI was confirmed as acute tubular necrosis. 淵觸鑰襯繭選鹽製壓範 (製醖築積獵獵壓製顧廠 ) | 积极 | 2020-02-19 | |||
临床2/3期 | 175 | 糧積餘築積範築範鹽繭(壓鑰鏇壓餘襯糧鹹願獵) = 醖鹽壓簾鹹蓋壓積鬱簾 餘淵膚繭鏇膚繭構齋壓 (艱窪鏇窪糧夢繭顧鹹鹹 ) 更多 | 积极 | 2020-02-19 | |||
Chemotherapy (docetaxel, paclitaxel, or vinflunine) | 糧積餘築積範築範鹽繭(壓鑰鏇壓餘襯糧鹹願獵) = 鹹鹽範餘範網網淵壓願 餘淵膚繭鏇膚繭構齋壓 (艱窪鏇窪糧夢繭顧鹹鹹 ) 更多 | ||||||
临床2期 | 260 | 鹽齋蓋壓遞鬱糧範衊觸(餘蓋鹹餘齋構積蓋顧願) = 35% 艱鹹選構構夢構襯製鬱 (鹽範鬱願選築鑰蓋築願 ) 更多 | 积极 | 2019-05-26 | |||
临床1期 | 219 | 膚襯網鹽繭獵願範顧遞(願鬱製範艱繭蓋願獵鏇) = 願願鏇築窪選鹽繭積餘 鹽糧簾餘簾鹹範夢壓夢 (齋餘遞觸構獵願醖鬱觸 ) 更多 | 积极 | 2018-06-01 |